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Abstract
Objective There is limited pharmacokinetic data available
for the combination artesunate + amodiaquine, which is
used widely to treat uncomplicated malaria. This study
examines the bioavailability and tolerability of a fixed
(200 mg artesunate + 540 mg amodiaquine) and loose
(200 mg+612 mg) combination with a 2×2 cross-over de-
sign in 24 healthy volunteers.
Methods Parent compounds and metabolites [dihydroarte-
misinin (DHA) and desethylamodiaquine (DEAQ)] were
measured by high-performance liquid chromatography–
electrochemical detection, and the area under the curve
(AUC)0-t and Cmax were compared by an analysis of vari-
ance (ANOVA) based on geometric least square means
using the Schuirmann two one-sided test.
Results The AUC0-t for total DHA and DEAQ were 1522 ±
633 and 30021 ± 14211 ng h/ml for the fixed products and
1688 ± 767 and 40261 ± 19824 ng h/ml (mean ± standard
deviation) for the loose products. The ANOVA showed no
statistical differences except for sequence effect for DHA.
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Introduction
Malaria occurs in 109 countries with 3.3 billion people at
risk of contracting the disease; 247 million cases of
malaria are reported annually [1]. The World Health
Organisation (WHO) recommends replacing monotherapies
with artemisinin combination therapies (ACTs) [2]. Accord-
ing to official figures, 49 million ACT courses were dis-
tributed in 2006, but real usage is likely to be much higher
[1].
Artesunate (AS) combined with amodiaquine (AQ) is
currently one of the most widely used ACTs and has been
adopted by 20 countries worldwide (19 in Africa) as the
first line treatment for malaria. Both AS and AQ are
currently administered as a loose formulation or in co-
blister packs; however, due the large number of tablets
involved, there is a possibility of patients failing to adhere
to their treatment regimen or complete their course of
therapy. To overcome this, a fixed-dose combination
treatment (AS/AQ) that provides a simplified regimen has
been developed and registered.
Artesunate and AQ have independent but complementa-
ry modes of action: the former is a short-lived, highly
potent artemisinin that provides a rapid reduction of
parasite biomass, whereas the latter has a longer half-life
to ensure the eradication of residual parasites [3]. Artesu-
nate [dihydroartemisinin-10α-hemisuccinate, molecular
weight (MW) 384] is considered to be a prodrug, as it is
rapidly and extensively converted via chemical and en-
zymatic pathways to its main bioactive metabolite, dihy-
droartemisinin (DHA; also referred to as artenimol, MW
284). Following oral intake, AS levels are transient, and
DHA is the predominant species; the two moieties are
roughly equipotent [4], and both contribute to parasite
killing. The pharmacology of AS and DHA, following oral
administration of AS, show considerable inter-individual
variation and are affected by disease status [5, 6]. The
elimination half-life (t½) of DHA averages 0.65–2.59 h [7,
8]. Amodiaquine is also considered to be a prodrug and is
rapidly and extensively converted to its main metabolite, N-
desethylamodiaquine (DEAQ), essentially in the liver by
cytochrome P 2C8 (CYP2C8) [9]. Unlike AS, AQ has a
negligible effect on parasites. In adults, the elimination
half-life of AQ is approximately 4 h [10], but DEAQ has
a much longer but variable half-life (2.5–18.2 days) [11,
12].
The pharmacology of oral AS, often co-administrated
with mefloquine, has been studied in both healthy volun-
teers and malaria patients. In contrast, despite years of
widespread use either alone or combined with AS,
pharmacological information on AQ is inadequate.
The aim of this study was to investigate the pharmaco-
kinetic properties, tolerability, and bioavailability of AS and
AQ when co-administered as either fixed or non-fixed
products in healthy normal volunteers.
Methods
Study design
This was an open, randomised, two-period crossover trial in
which the PK properties, tolerability and bioavailability of
AS + AQ when administered as a fixed-dose or non-fixed
dose preparation were compared. The study was conducted
in accordance with international Good Clinical Practice
standards and monitored. The protocol was approved by the
Institution Ethical Review Board of the Teaching Hospital
Universiti Sains Malaysia, Kota Bharu, Malaysia and the
WHO Ethics Committee, and was authorised by the
Malaysian Ministry of Health.
A total of 24 healthy normal volunteers (HNVs), aged
between 21 and 45 years, were randomised to receive either
the non-fixed (NF) or the fixed (F) combination regimen
during Study Period 1. The randomisation process was
carried out by using a table of random numbers to
select 24 consecutive, unduplicated numbers between 01
and 24. After a wash-out period of 60 days (5 × t½
DEAQ 45–90 days), subjects entered Study Period 2 and
were given the alternative treatment combination. Thus,
one group of subjects received the fixed, followed by the
non-fixed combination (F–NF), while the other group
received the non-fixed, followed by the fixed product
(NF–F).
Drugs were administered under fasting conditions. Each
subject received a single total dose of 200 mg AS plus
540 mg AQ when given the fixed product, and 200 mg AS
plus 612 mg AQ with the non-fixed product. These doses
represent 1 day of a 3-day therapeutic course and were
selected to be as close as possible to the target treatment
doses of 4 and 10 mg kg
−1 day
−1 for AS and AQ, re-
spectively. The doses of AQ in the fixed and non-fixed for-
mulations were different because of the different strengths
of the formulations used.
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The fixed-dose co-formulated product (manufactured by
Creapharm, France, batch no. CPM 5856) consisted of
100 mg AS and 270 mg AQ base; the loose non-fixed
product consisted of AS (Arsumax 50 mg tablets; Sanofi-
Aventis, Paris, France/Guilin Pharma Co, China, batch no.
31201) and AQ (Flavoquin 153 mg of AQ base; Hoechst
Marion Roussel, Sanofi-Aventis, batch no. 4).
Entry criteria
Volunteers were recruited by means of advertisements
placed at the teaching hospital of the Universiti Sains
Malaysia, Kota Bahru. Written informed consent was
required before the volunteers were allowed to participate
in the trials. Entry criteria included a negative pregnancy
test for women; a negative malaria thick smear; no sig-
nificant abnormal findings on the medical history or clinical
examination (including electrocardiogram, haematology,
liver and renal function tests); no history of antimalarial
treatment in the preceding 2 months; no other drugs or
medications in the preceding week; adequate venous
access; no abuse of alcohol or recreational drugs; no known
allergy to the study drugs; smokers (>10/day) were also
excluded.
Drug assay
Sampling
Blood samples were collected at pre-dose, at 0.25, 0.5,
0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h post-
medication and at 5, 7, 14, 21, 28, 35, 42 and 60 days post-
medication. Day 60 for Study Period 1 and Day 0 for Study
Period 2 coincided. Specimens in the first 12 h of each
study period were drawn via an indwelling catheter; for the
remaining periods, blood samples were drawn by direct
venipuncture. Blood samples (5 ml each) were stored in
heparinised vacutainer tubes for further processing. The
levels of AQ and DEAQ were measured at all time points,
while those of AS and DHAwere measured at pre-dose and
at 0.25, 0.50, 0.75, 1.0, 1.5, 2, 3, 4, 6, 8 and 12 h after drug
administration. After centrifugation of blood samples, the
plasma samples were immediately transferred to separate,
appropriately labelled plastic cryotubes and frozen at
−70°C.
Analytical methods
The assays were carried out at the Centre for Drug
Research, Universiti Sains Malaysia, Penang, Malaysia.
Artesunate and dihydroartemisinin This assay method was
validated with minor modifications of a previously pub-
lished method [13]. The analyses of AS and DHA were
carried out on BAS 200A high-performance liquid chro-
matography/electrochemical (HPLC–EC; BAS, West
Lafayette, IN) systems operating at reductive mode.
Chromatographic separation of AS, DHA and the internal
standard artemisinin (QHS) was obtained at room temper-
ature (25°C) on an Inertsil C4 column (internal diameter
150× 4.6 mm , particle size 5 μm; GL Sciences, Tokyo,
Japan). The mobile phase consisted of acetonitrile (ACN)
and 0.05 M acetic acid (40:60 %v/v) adjusted to pH 4.0
with 1 M NaOH. The flow rate was 1.50 ml/min. Detection
was performed in the reductive mode at −1000 mV in an
oxygen-free environment. The HPLC-EC (reductive) sys-
tem produced a linear response for the concentration of AS
and DHA varying from 20 to 1600 ng/ml respectively. The
extraction recoveries of AS, DHA and QHS were above
79% with a coefficient of variation (CV) not exceeding
13%. The lower limit of quantification (LLOQ) of AS was
20 ng/ml, and its accuracy and CV were −0.1 and 4.4%,
respectively; the corresponding values for DHA (LLOQ
20 ng/ ml) were −2.6 and 6.0%, respectively. The within-
day and day-to-day precision for both AS and DHA at low,
medium and high concentrations did not exceed 15%.
Amodiaquine and N-desethylamodiaquine The analyses of
AQ and DEAQ were carried out on BAS 200A HPLC–EC
systems coupled to an EC detector operating at oxidative
mode. The analysis of AQ, DEAQ and the IB-DEAQ
(internal standard) was carried out at room temperature
(25°C) using an Inertsil C4 column (internal diameter 150×
4.6 mm, particle size 5 μm; GL Sciences). The mobile
phase consisted of ACN and 0.05 M KH2PO4 (11:89, %v/v)
adjusted to pH 4.0 with orthophosphoric acid. The flow rate
was 1.0 ml/min. Detection was performed in the oxidative
mode at +800 mV. The extraction recoveries of AQ, DEAQ
and IB-DEAQ were all above 80%, with a CV of less than
11%. The HPLC–EC (oxidative) system produced a linear
response for the concentration of AQ and DEAQ that
varied from 20 to 1600 ng/ml, respectively. The LLOQ of
AQ and DEAQ were 20 ng/ml, and the accuracy and
variation were of 4.2 and 5.0%, respectively; the CV were
7.5 and 7.3%, respectively. The within-day and day-to-day
precision for both AQ and DEAQ were less than 15%.
Pharmacokinetic analyses
We measured the parent drug and main active metabolite of
both compounds (AS + DHA and AQ + DEAQ). In
addition, the total DHA concentration was estimated by
summation of HPLC-determined DHA and DHA equiva-
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each individual. The DHA equivalence was determined by
converting the drug concentration of AS to DHA stoichio-
metrically. The pharmacokinetic parameters Cmax,T max,
and AUC0-t were determined using model independent
formulae [14]. Maximum achieved concentration (Cmax)
and time to achieve the maximum concentration (Tmax)
were obtained from a visual inspection of the plasma con-
centration versus time curve. Area under the concentration–
time curve from 0 to t (AUC0-t, where t = last quantifiable
drug concentration) was calculated using the linear trape-
zoidal rule: AUC0-t=[(C1+C2)/2(t2 -t 1)]+…..+[(Cn–1+Cn)/
2( t n -t n–1)]. The AUC0-∞ (up to infinity) was calculated by
the formula AUC0-t +C t/ 1z where Ct is the concentration
at the last quantifiable time. From the terminal log-linear
(disposition) phase, a first order elimination rate constant
(1z) was estimated by linear regression and terminal half-
life value (t½) was estimated from at least three concentra-
tion values using the equation (t½) = ln2 / λz. The mean
residence time (MRT) was calculated for both parent
compounds and metabolites as the AUMC/AUC where
AUMC is the area under the first moment-versus-time
curve.
Bioavailability
For bioequivalence studies, the 1992 Federal Drug Agency
(FDA) guidance recommends that the statistical analysis for
pharmacokinetic measures, such as AUC and Cmax,b e
based on the two one-sided tests procedure that examines
whether the average values for the pharmacokinetic
measures determined after administration of the test and
reference products were comparable. This approach is
termed average bioequivalence and involves the calculation
of a 90% confidence interval (CI) for the ratio of the
averages (population geometric means) of the measures for
the test and reference products. To establish bioequivalence,
the calculated confidence interval should fall within a limit,
usually between 80 and 125%, for the ratio of the product
averages [16]. This method is equivalent to the corre-
sponding two one-sided tests procedure with the null
hypothesis of bioinequivalence at the 5% significance level
[17].
Bioavailabilities of the fixed and non-fixed AS/AQ
formulations were compared using mean AUC0-t.I n
addition, we tested the Cmax,t max and t½. Differences in
the ln mean AUC0-t and ln mean Cmax between treatment
periods were compared using analysis of variance
(ANOVA). The model allowed for the effects of formula-
tion, period, sequence and subjects within sequence on the
observed parameter.
For AUC0-t and Cmax, we applied the Schuirmann’s two
one-sided tests (TOST) to compute the probability to reject
the null hypothesis (i.e. that the two products are different).
The Tmax and t½ values were compared by the Wilcoxon
signed rank test. All statistical analyses were performed
with the statistical software package EquivTest ver. 2.0
[15].
Safety
We used standard definitions for adverse events (AEs) and
serious adverse events (SAEs). All subjects were assessed
clinically at baseline. Reporting of symptoms was solicited
during the course of the study. Clinical AEs were described
by the attending physician in terms of signs and symptoms
and classed by body system: gastrointestinal (GI), cardio-
vascular (CVS), central nervous system (CNS), etc. They
were assessed for severity [mild (Grade 1), moderate
(Grade 2), severe (Grade 3), very severe (Grade 4)] using
the Common Toxicity Criteria (CTC V3.0; National Insti-
tute of Health, Bethesda, MD).
Laboratory examinations (haematology, liver and renal
functions) were conducted at Day 0, Day 7 and Day 28 of
each study period. Twelve lead electrocardiograms (ECGs)
were performed at baseline and at 1, 2, 4, and 24 h post-
drug administration; this was repeated for Study Period 2
(results to be reported in a separate analysis). All AEs that
occurred during the study were recorded with the date and
time of occurrence and the date the abnormal finding
disappeared.
The chi-squared test was used to compare the frequen-
cies of: (1) AEs between groups and (2) normal/abnormal
laboratory values in shift tables. The Cochran–Mantel–
Haentzel statistic was used to assess the general association
of the treatment groups and the occurrence of at least one
AE in a subject during the two study periods.
Results
Disposition and baseline characteristics
Study subject disposition is shown in Fig. 1. Two subjects
were excluded from the overall data analysis: one subject
received only the non-fixed AS/AQ combination in Study
Period 1, but was later withdrawn from the study because
of acute gouty arthritis (this event was a recrudescence of
prior disease that was judged to be probably related to the
study drug); the other subject had an extraordinarily high
DEAQ AUC0-t (approx. ten10-fold higher than that with the
fixed combination) after having received the non-fixed
combination. This observation was deemed to be an
unexplainable outlying result, and all pharmacokinetic data
pertaining to this subject were excluded from the analyses.
The threshold for outliers was calculated as recommended
812 Eur J Clin Pharmacol (2009) 65:809–821for skewed distributions from the interquartile range.
Inclusion of this subject’s data in the analyses did not alter
any bioequivalence conclusions (data not shown). There-
fore, 23 of the original 24 subjects were analysed for drug
disposition (six males, 17 females) and 22 for comparative
bioavailability.
The mean age of the subjects was 27.3±6.8 years.
Medical history and vital signs were similar in the two
groups except pulse rate (p=0.02).
Pharmacokinetics
After oral administration, AS and AQ were rapidly
absorbed and underwent rapid and extensive metabolism
to their respective metabolites, DHA and DEAQ. The
plasma levels of both DHA and DEAQ were manifold
higher and persisted for longer than their respective parent
compounds. The pharmacokinetic properties of AS, DHA,
AQ, DEAQ and total DHA are given in Table 1; the plasma
time–concentration profiles of AS, DHA, AQ and DEAQ
are shown in Fig. 2.
The relative bioavailabilities of total DHA and DEAQ
expressed as AUC0-t produced by the fixed product were
similar to those of the non-fixed product (F:NF ratios 102.3
and 107%, respectively). The analysis of comparative
bioavailability of the two products is shown in Table 2.
There was no evidence of carry-over effects between
subjects except for the AQ (parent) AUC, no period effect
except for total DHA AUC and no drug effects within
subjects between the two formulations except a marginal
effect for AQ and DEQA AUC. For both total DHA and
DEAQ, the AUC0-t values obtained with the fixed
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Fig. 1 Profile of study subject disposition
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products [data not shown: provided as Electronic Supple-
mentary Material (ESM)]. The values produced by the fixed
product appear to be tighter than those provided by the non-
fixed product for both total DHA and DEAQ (data not
shown: provided as ESM).
Based on the 90% CI of the geometric least squares
means ratios (GLSMR), the Cmax and AUC0-t values
produced with the fixed combination with respect to the
non-fixed combination were within the upper boundary
(125%) but extended beyond the lower boundary (80%) of
the confidence interval for all moieties except AS Cmax,
which was also >125% (Table 2). The Shuirmann TOST
was non-significant for lower limits, while the upper limits
of the one-tailed t-statistics were significant (again except
for AS Cmax) (Table 2). Plasma Cmax and AUC0-t of total
DHA were lower in the fixed combination by 12 and 8%,
respectively, for total DHA and by 15 and 14%, respec-
tively, for DEAQ. The Tmax was significantly shorter in
subjects given the fixed product for total DHA, AS and
DHA, longer for AQ and not different for DEAQ (Table 2).
The within-subject variation (% CV) of the AUC0-t between
the non-fixed and the fixed combination were 4.3% for total
DHA and 3.6% for DEAQ. The t½ for both formulations
was not bioequivalent (Table 2).
Mean residence times (see Table 1) were compared
between the fixed and non-fixed combination for AS,
DHA, AQ and DEAQ using a t test. The comparisons were
found to be non-significant. The mean ± standard deviation
AUC ratios AS:DHA were 0.08±0.12 and 0.09±0.06 for
the fixed and non-fixed product, respectively; the
corresponding values for AQ:DEAQ were 0.002±0.002
and 0.003±0.004, respectively, with no difference between
the two formulations.
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Fig. 2 Concentration–time pro-
files of artesunate (AS)/dihy-
droartemisinin (DHA)( a) and
amodiaquine (AQ)/desethylamo-
diaquine (DEAZ)( b). Filled
diamonds Fixed product, open
boxes non-fixed product
814 Eur J Clin Pharmacol (2009) 65:809–821When individual subjects were considered, there was no
consistent direction of change in any parameter measured.
Figure 3 depicts individual data with the two products of
AUC0-t for total DHA and DEAQ. The ranges of values
were similar for the fixed and non-fixed combination, and
changes went both ways between the two combinations: for
DHA and DEAQ, values increased in 46 and 35% of patients,
respectively, and decreased in 54 and 65%, respectively.
Safety
Both formulations were tolerated. Overall, 42 events were
reported. During Study Periods 1 and 2, 45 and 55% of
subjects had at least one AE. By drug group, the proportions
were: (1) 67 (F) versus 36% (NF) in Study Period 1, and (2)
45 (F) versus 58% (NF) in Study Period 2.
There was no statistically significant difference between
sequences (62 and 41% of subjects in the F–NF and NF–F
sequences had at least one AE, p=0.14) or between Study
Period 1 and 2 (p=1.0). The Cochran–Mantel–Haentzel
statistic for a general association of the treatment groups
and the occurrence of at least one AE in a subject during
the two periods of the study showed no significant dif-
ference (p=0.56)
The most common AEs were liver enzyme abnormalities
(21% of all AEs), flushing (17%), dizziness and giddiness
(14% each) and nausea (7%); all other events contributed
<5%. The body systems most commonly affected were the
gastro-intestinal system (35% of AEs including liver en-
zyme abnormalities) and the central and peripheral nervous
system (30% of all AEs).
There was no significant difference in the drug–event
relationship between the two groups: 10/23 events in
Group 1 and 13/20 in Group 2 were judged to be
probably or definitely related to study drug (43 and 65%,
respectively).
The main laboratory parameters monitored during the
study are presented in Table 3. At screening, 18 subjects
had mildly abnormal laboratory values (Grade 1) and one
subject exhibited a Grade 2 alanine transaminase (ALT)
concentration. Pre-treatment, there was one case of Grade 1
neutropaenia (1600 × 10
6/l) in the group that received the
non-fixed combination first; this subject returned to normal
by Day 7 of Study Period 1. One subject was inadvertently
Table 2 Comparative bioavailabilities of fixed and non-fixed combinations of artesunate and amodiaquine. Combinations are measured as total
DHA and DEAQ
Compound Pharmacokinetic measure ANOVA GLSM Schuirmann TOST
L/U p-value
Carry-over Period Drug CV (%) Fixed Non-fixed Ratio 90%CI
Total DHA AUC0-t (ng h/ml) 0.56 0.02 0.38 4.31 1398.3 1522.2 0.9 0.79, 1.08 0.08/0.002
Cmax (ng/ml) 0.63 0.23 0.28 8.7 714.8 870.4 0.8 0.60, 1.12 0.44/0.01
Tmax
a (h) 0.53 1.03 0.51 0.03 (Wilcoxon)
T½ (h) 0.78 0.93 0.13 130.56 1.49 1.25 1.19 0.98, 1.45 0.002/0.34
AS AUC0-t (ng h/ml) 0.53 0.12 0.63 8.85 168.04 182.4 0.92 0.72, 1.17 0.17/0.0224
Cmax (ng/ml) 0.46 0.19 0.91 11.89 281.08 291.96 0.96 0.67, 1.38 0.1923/0.1123
Tmax
a (h) 0.26 0.55 0.47 0.005 (Wilcoxon)
T½ (h) 0.47 0.80 0.75 −175.12 0.48 0.59 0.81 0.27, 2.38 0.49/0.23
DHA AUC0-t (ng h/ml) 0.85 0.07 0.24 8.51 1257.12 1430.97 0.878 0.73, 1.06 0.198/0.0019
Cmax (ng/ml) 0.97 0.14 0.10 8.70 550.35 736.52 0.74 0.56, 1.00 0.6542/0.0032
Tmax
a (h) 0.56 1.07 0.52 0.06 (Wilcoxon)
T½ (h) 0.93 0.78 0.29 102.14 1.47 1.32 1.11 0.94, 1.31 0.002/0.11
AQ AUC0-t (ng h/ml) 0.03 0.43 0.0415* 8.60 97.34 136.75 0.71 0.54, 0.94 0.761/0.0018
Cmax (ng/ml) 0.06 0.74 0.28 8.87 53.89 63.69 0.85 0.71, 1.03 0.26/0.0012
Tmax
a (h) 0.85 1.62 0.52 0.04 (Wilcoxon)
T½ (h) 0.64 0.34 0.16 41.62 1.42 2.60 0.55 0.24, 1.24 0.85/0.05
DEAQ AUC0-t (ng h/ml) 0.63 0.45 0.05 3.64 26630 35000 0.8 0.6, 0.9 0.65/0.0003
Cmax (ng/ml) 0.45 0.1 0.17 5.32 749.1 872.7 0.9 0.7, 1.0 0.26/0.001
Tmax (h) 1.39 1.68 0.83 0.14 (Wilcoxon)
T½ (h) 0.08 0.92 0.60 14.46 159.03 188.09 0.84 0.49, 1.45 0.43/0.11
GLSM, Geometric least squares mean; CI, confidence interval; CV, coefficient of variance
Numbers under carry-over, period and drug are p values. Values in the Fixed and Non-fixed columns are means
aComparison by arithmetic means and Wilcoxon test (non-parametric approach)
Eur J Clin Pharmacol (2009) 65:809–821 815enrolled with a Grade 2 baseline value of ALT; this also
normalised during follow-up.
Four subjects presented five abnormal laboratory values
during the study: three were Grade 3 and two were Grade 4.
One subject with a baseline uric acid value of 546 μmoll/l
experienced two episodes of Grade 4 (uric acid >
590 μmoll/l) elevation in uric acid at Day 7 and 29 of
Study Period 1, with values of 598 μmoll/l and 636 μmoll/l,
respectively. This patient had a history of gout arthritis and
was withdrawn from the study after Study Period 1.
Three individuals had one Grade 3 deviation each: (1)
ALT = 156 U/L (5–20 × upper normal limit) at Day 60 of
S t u d yP e r i o d2( s e q u e n c eN F –F); (2) hypocalcaemia
calcium=1.67 mmol/l (1.5–1.75 × upper limit) (sequence
NF–F); (3) hyponatraemia sodium=124 mmol/l (120–130 ×
upper limit) at Day 7 of Study Period 1. No volunteers
developed neutropaenia during follow-up.
No serious AEs occurred. One subject was withdrawn
due to an exacerbation of pre-existing gout which had not
been declared or detected on recruitment. The subject was
treated with non-steroidal anti-inflammatory drugs and
ultimately recovered.
Discussion
The results of this study on adult Malaysian healthy
volunteers using a cross-over design shows that AS and AQ
are readily absorbed and well tolerated when co-administered
either as loose products (in a non-fixed combination) or as a
fixed-dose combination. However, the two combinations
cannot strictly be defined as "bioequivalent".
We measured and reported the disposition of the parent
compounds and their metabolites separately, but we
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Fig. 3 Stick plots of the area
under the concentration–time
curve from time zero to last
quantifiable measurement
(AUC0-t) of total DHA (a), AS
(b), DHA (c), AQ (d) and
DEAQ (e) of the fixed versus
non-fixed products for individu-
al subjects (numbers)
816 Eur J Clin Pharmacol (2009) 65:809–821considered the primary analytes (total DHA for AS, and
DEAQ for AQ), as the biologically and clinically relevant
indicators of drug absorption. For AS and DHA, the reason
for combining the two measurements (after stoichiometrical
conversion of the measured AS values) is that the two
compounds have comparable antimalarial potencies [4] and
conversion of AS to DHA is rapid (chemical hydrolysis
starts in the stomach). This makes their pharmacological
effects indistinguishable over their very short residence
time. This approach is supported by the correlation between
the bioassay and the measurement of the two separate
products [18], the combined measurement may be the better
parameter to use for pharmacokinetic–pharmacodynamic
analyses. Although AQ is more potent in vitro than its
metabolite, the systemic exposure to AQ is considerably
lower than that to DEAQ [10, 12], which is solely
responsible for sustained antimalarial activity after AS/
DHA have been eliminated. The ratio between the AUCs of
AS to DHA and AQ to DEAQ was approximately 8.5%
and 0.02%, respectively; the AQ t½ was one tenth of that
for DEAQ.
In this study we used different descriptive and statistical
approaches to assess and compare the product bioavail-
abilities, and these generally gave consistent results. It is
commonly accepted that the two primary parameters used
for measuring the extent of drug absorption are area under
the curve (AUC) and maximum concentration (Cmax), both
logarithmically transformed. To confirm bioequivalence of
the two products, the geometric mean ratios (plus 90% CI)
of these metrics should lie within an 80–125% window of
acceptance [16]. We used the ANOVA F test to identify the
source of variance, be it a product, subject or period effect.
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Table 3 Laboratory parameter measures by product over time
Laboratory parameters Product Baseline Day 8 Day 29 Day 60
Mean SD Mean SD Mean SD Mean SD
Red rood cells (×10E12/l) F 4.8 0.3 4.9 0.4 4.9 0.4 4.9 0.4
NF 4.9 0.3 4.9 0.4 5 0.4 4.9 0.3
Haemoglobin (g/l) F 14.1 1 14.2 1.2 14 1.1 14.1 1.1
NF 14.2 1.1 14.2 1.1 14.3 1 14.1 1.2
Haematocrit (%) F 41.2 3.5 41.5 3.3 41.5 3.1 41.6 3.2
NF 41.8 2.6 41.5 3.2 42 3 41.7 3.2
Platelets (×10E9/l) F 299 42 318.2 71.6 303.9 72.1 317.4 79.2
NF 304.1 84.7 314.3 68.5 294.9 68.2 315.3 79.2
White Blood Cells (×10E9/l) F 6.7 1.3 6.8 2.1 6.8 1.2 7 1.8
NF 6.5 1.2 6.9 1.6 6.6 1.6 6.6 1.4
Neutrophils (×10E9/l) F 3.7 0.9 3.7 1.8 3.7 1 3.9 1.3
NF 3.5 1.1 3.9 1.3 3.6 1.4 3.5 0.9
Alanine transaminase (U/l) F 30.7 26.6 34.4 32.5 32.8 34.8 29.7 31.8
NF 22.5 19.2 19.5 12.6 20.7 10.5 31.7 21.3
Aspartic transaminase (U/l) F 28.9 12.1 27.5 11.2 27.7 13.2 26.3 13.7
NF 22.3 9.3 25 13.3 22.8 4.9 26.7 10.2
Alkaline phosphatase (U/l) F 80.1 12.1 79.1 17.1 74.7 17.9 74.7 15.2
NF 69.5 14.4 70.7 15.7 75.7 15 75.6 15.5
Calcium (nmol/l) F 2.4 0.1 2.4 0.2 2.4 0.1 2.5 0.1
NF 2.4 0.1 2.4 0.1 2.5 0.1 2.4 0.1
Potassium (nmol/l) F 4 0.4 4.1 0.4 4.1 0.3 4.1 0.3
NF 4 0.4 4.3 0.6 4 0.2 4.1 0.3
Sodium (nmol/l) F 140.7 2.7 136.5 1.8 137.9 2.1 141.7 1.6
NF 139.6 2.7 137.2 3.6 137.8 2.3 141.1 1.7
Uric acid (mmol/l) F 361.8 64.6 361.8 74.6 357.4 80.5 345.1 53.7
NF 352.2 46 353.9 56.4 358.4 55.1 347.8 54.1
Creatinine (mmol/l) F 104.5 13.1 107.4 13.1 102.2 11.4 103.3 12.2
NF 102.3 12.5 99.9 10.1 103.9 11.2 104.6 12.6
NF, Non-fixed combination; F, fixed combination
818 Eur J Clin Pharmacol (2009) 65:809–821It is important to appreciate that the tested hypothesis is
stated as the “alternative” hypothesis; the null hypothesis
is rejected in favour of the alternative hypothesis if there is
sufficient statistical evidence against the null hypothesis.
With the Schuirmann two one-sided tests, this is broken
down into two one-sided hypotheses (above and below the
allowed range), and two separate t tests are applied. For
two products to be considered bioequivalent, the null
hypothesis of bioinequivalence must be rejected (the test
must be significant, normally with α=0.05).
In general, the metrics we obtained with the fixed
combination were well within the variance of the non-
fixed combination. However, the strict criteria of bioequi-
valence were not met entirely. The mean geometric mean
ratios for the AUCs obtained with the fixed versus non-
fixed were 92 and 86% for total DHA and DEAQ,
respectively; when the individual subjects’ AUC were
compared, the corresponding mean values were 102 and
107%, respectively. The 90% CI around the geometric least
squares means ratios of the AUC with the fixed product
over the non-fixed formulation were within the upper
bound, but below the lower bound (78 and 62% for total
DHA and DEAQ, respectively). The two products
generated similar AS/DHA and AQ/DEAQ plasma–time
profiles, but inter-subject variability, as expected, was
wide, and this may have affected our interpretation of the
results.
Despite not meeting the defined criteria for bioequiva-
lence, certain elements indicate that the two formulations
do behave in a similar way: no significant difference was
seen in the AUC ratios (AS:DHA and AQ:DEAQ) or the
MRT of the individual parent compounds and metabolites
between the fixed and non-fixed formulation. The AUC
above the inhibitory concentration is conceivably the best
predictor of antimalarial efficacy for both a drug with a
long residence time such as AQ/DEAQ, and short-lived
drugs, such as AS/DHA, while Cmax versus inhibitory
concentration may also be of some value for the latter.
Here, the Cmax of total DHA obtained with a single 200 mg
dose was 802 (range 270–2179) and 1077 ng/ml (range
348–3300 ng/ml) with the fixed and non-fixed combina-
tion, respectively. Even the lowest values obtained were
approximately 170- and 20-fold higher than the mean half
maximal inhibitory concentration (IC50; 1.62 ng/ml; upper
95% CI: 13.1 ng/mL) of Plasmodium falciparum parasites
from the Thai–Burmese border, respectively [4]. A note of
caution should be introduced, however, when extrapolating
from in vitro data to in vivo situations, particularly for the
artemisinin-type compounds. While clinical failures to
artemisinins are being reported from Western Cambodia
[19], there is no clear association with increased IC50s, and
the in vitro test as customarily performed may not be ideal
for this type of compound.
The major question, then, is whether this lack of strictly
defined bioequivalence is clinically relevant in patients.
Comparison with biological data indicates that these
differences are not expected to alter clinical responses in
patients. Indeed, looking at available clinical data, a
randomised controlled trial with a non-inferiority design
comparing the loose and fixed-dose combinations has
found similar efficacy rates for both combinations in
paediatric falciparum malaria in Burkina-Faso [20]. The
80–125% limits for bioequivalence should also be based on
the therapeutic window and pharmacokinetic/pharmacody-
namic characteristics of a drug and should thus consider
safety as well as efficacy [17]. For both drugs, and
particularly AQ, which may have an increased risk of
toxicity with higher doses [21, 22], exposure with the fixed
formulation is well within the upper limit of acceptance. It
should also be noted that the dose of AQ in the non-fixed
combination was 13% higher than that in the fixed
combination owing to different tablet strengths and that
the data were not normalised by body weight in these
analyses.
Irrespective of the discussion concerning the bioequiva-
lence of the fixed and non-fixed formulation of AQ and AS,
this study still adds to the currently limited information on
the disposition of AQ. Two recent studies have reported
considerably different pharmacokinetic characteristics of
AQ [23, 24]. These differences, however, could be ascribed
to different subject populations, disease effect and analyti-
cal assays: one study measured DEAQ in children with
malaria from PapuaNew Guinea treated withAQ(10 mg/kg)
for 3 days [23]; the other study investigated South African
adult healthy volunteers given a single dose of AQ alone
(10 mg/kg) [24]. The South Africa paper also reported the
effects of co-administering AS and AQ with a three-phase
cross-over design. This co-administration resulted in an
approximately 35% reduction of the AUC for both drugs.
Exposure to AS + AQ (measured by Cmax and AUC) in the
South African volunteers was approximately one-third of
that in our study. This difference does not seem to be
related to the assay used, as the detection limit of the
HPLC–ECD used in our study is higher than that of the
liquid chromatography/mass spectrometry used in the South
African study (LLOQ 20 and 5 ng/ml, respectively). One
possible explanation of this observation is that polymor-
phisms of the CYP2C8 enzyme could contribute to
different rates of drug metabolism [25].
For AS + AQ and other currently available ACTs, the
selection of combination treatment doses has been largely
empirical, aiming to achieve the same doses as if given
individually. The dose–response relationship for AS has
been described [26], but there is currently very little
information, especially in malaria patients, on the pharma-
cokinetic/pharmacodynamic properties of AQ or the AS +
Eur J Clin Pharmacol (2009) 65:809–821 819AQ combination. A recent study exploring data from
children in Zanzibar and Papua New Guinea derived the
population kinetics of DEAQ and found a significant but
weak correlation between the levels of DEAQ on Day 7 and
antimalarial efficacy [27].
In clinical trials of uncomplicated falciparum malaria,
co-administration of AS + AQ has been shown to be more
effective than AQ alone [28] and is generally effective
across Africa, although with regional variations, depending
on the sensitivity of the local parasite strains to AQ [29].
Since the majority of these studies were conducted with
individually formulated AS and AQ, which were either the
same products as those used here for reference or equiva-
lent products, combining the two drugs into a single tablet
can be expected to produce the same clinical results, given
that the levels of exposure achieved in this study were
similar.
With respect to AS, the main disposition parameters
were similar to those of a previous study in Malaysian
volunteers following a single oral dose of 200 mg [30]. The
AS + AQ combination was well tolerated, and only minor
changes in safety parameters occurred, although the sample
size was too small to detect rare events. In particular, there
was no indication of liver or haematological toxicity, the
two toxicities that have caused fatalities in the past when
AQ was used as prophylaxis [31]. Although the number of
healthy subjects was limited, each was exposed twice to
AQ and followed for a long time. It has been suggested that
repeat exposure to AQ may favour toxicity through the for-
mationofa quinoneiminethatmayleadtoimmunoglobulinG
immune-mediated liver and neutrophil toxicity. Asymptom-
atic, self-resolving hepatitis was reported in a healthy female
subject in the South African study [32]. Clinicians should be
wary of this possibility in clinical practice.
With the wider use of the new fixed-dose AS + AQ
combination, further studies on the disposition of these
compounds in malaria patients are warranted, and safety
should continue to be monitored.
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